Product category:
Cell/tissue handling and counting
News Release from: Microbix Biosystems
Edited by the Laboratorytalk Editorial
Team on 24 December 2002
Microbix raises financing to continue
development
Microbix Biosystems has announced that it has completed a Canadian $500,000 Principal amount 8% convertible debenture, in a non-arms length transaction with an existing shareholder.
Microbix Biosystems has announced that it has completed a Canadian $500,000 Principal amount 8% convertible debenture, in a non-arms length transaction with an existing shareholder The principal of the debenture is convertible into common shares at $0.90 per share for eight years
This article was originally published on Laboratorytalk on 20 Mar 2003 at 8.00am (UK)
Related stories
Double anniversary at Focus
Supplier of one quarter of the world's haematology analysers celebrates its twentieth birthday, while its parent company celebrates its fiftieth
Proceeds will be used for working capital.
William J.Gastle, President and Chief Executive Officer said "Now that ThromboClear has been partnered, as announced last month, we are concentrating on the next products in our pipeline.
"These working capital funds will be used to advance products already in development, to expand new development activities and to explore in-licensing other products and technologies for the core business." Microbix specializes in developing and manufacturing cell culture-derived biologics for an emerging world market of biotherapeutic drugs and vaccines.
It makes reagents for building diagnostic products and tools used in biotechnology research.
The Company has expertise in advanced culture, purification, process scale-up and validation technologies.
Its objective during the next decade is to become significantly involved in the expected multi-billion dollar generic biotherapeutics market in North America.
• Microbix Biosystems: contact details and other news
• Email this article to a colleague
• Register for the free Laboratorytalk email newsletter
• Laboratorytalk Home Page

